8 papers in the library · 77 citations · publishing 2021-2026
J Affect Disord February 23, 2026 Xiaofeng Lan, Zitao Wu, Chengyu Wang et al.
Multiple peripheral inflammatory markers in adolescents with major depressive disorder treated with repeated esketamine infusions: results from a randomized controlled trial.
CNS Neuroscience & Therapeutics March 1, 2025 Zerui You, Xiaofeng Lan, Chengyu Wang et al. 1 citation
Despite the clinical benefits of ketamine in treating major depressive disorder (MDD), some patients exhibit drug resistance, and the intricate mechanisms underlying this await comprehensive explication. We used metabolomics to find biomarkers for ketamine efficacy and uncover its mechanisms of action. The study included 40 MDD patients treated with ketamine in the discovery cohort and 24...
Cell Biology and Toxicology January 10, 2025 Nan Zhou, Xiaolei Shi, Runhua Wang et al. 1 citation
Major depressive disorder (MDD) is characterized by persistent feelings of sadness and loss of interest. Ketamine has been widely used to treat MDD owing to its rapid effect in relieving depressive symptoms. Importantly, not all patients respond to ketamine treatment. Identifying sub-populations who will benefit from ketamine, as well as those who may not, prior to treatment initiation, would...
Current Neuropharmacology 2025 Wei Zheng, Limei Gu, Jianqiang Tan et al. 1 citation
Growing evidence suggests that repeated-dose intravenous ketamine in patients with depression had rapid antianhedonic effects. However, a comparison of the antianhedonic effects of repeated-dose intravenous ketamine between younger adults and older depressed patients has not been examined. To the best of my knowledge, this study with a total of 135 patients with major depressive episodes (MDE)...
Translational Psychiatry August 6, 2024 Chengyu Wang, Xiaofeng Lan, Weijian Liu et al. 6 citations
There is insufficient evidence to guide dose and frequency optimization with repeated-dose ketamine for depression. This study assessed the value of symptomatic non-improvement after the first few ketamine infusions as a predictor of overall non-response in depression for early decision-making to discontinue treatment. A total of 135 individuals with major depressive disorder or bipolar...
European psychiatry : the journal of the Association of European Psychiatrists April 4, 2024 Haiyan Liu, Chengyu Wang, Xiaofeng Lan et al. 7 citations
Amygdala subregion-based network dysfunction has been determined to be centrally implicated in major depressive disorder (MDD). Little is known about whether ketamine modulates amygdala subarea-related networks. We aimed to investigate the relationships between changes in the resting-state functional connectivity (RSFC) of amygdala subregions and ketamine treatment and to identify important...
Journal of Affective Disorders December 1, 2021 Wei Zheng, Lingna Gu, Chen-Hui Sun et al.
OBJECTIVES Anhedonia is a common, persistent, and disabling phenomenon in patients with major depressive disorder (MDD) and bipolar depression (BD). This study was conducted to investigate the comparative effectiveness of repeated ketamine infusions in treating anhedonia in Chinese individuals suffering from MDD and BD. METHODS Ninety-seven individuals suffering from MDD (n=77) or BD (n=20)...
Journal of Neuroinflammation September 15, 2021 Yanling Zhou, Chengyu Wang, Xiaofeng Lan et al. 61 citations
Treatment-resistant depression (TRD) and pain frequently coexist clinically. Ketamine has analgesic and antidepressant effects, but few studies have evaluated individual differences in antidepressant outcomes to repeated ketamine in TRD patients with comorbid pain. Our aims were to determine the difference in ketamine’s antidepressant effects in TRD patients with or without pain and then to...